Radioligand therapy using combination of Ac-225 and Lu-177 labelled PSMA ligands for progressive end-stage metastatic prostate cancer: effective trade-off between response and toxicity

Conclusions: TANDEM-PLRT, concomitantly administering Ac-225 and Lu-177 PSMA-617, seems to be feasible, safe and effective in end-stage metastatic prostate cancer, refractory to Lu-177 PSMA. The administered radioactivity of Ac-225 PSMA can be lowered and the risk of dose-limiting toxicity (xerostomia, xerophthalmia etc.) be minimized. There might be a potential synergistic effect using two radionuclides with different emission characteristics.

Source: Journal of Nuclear Medicine - May 20, 2019 Category: Nuclear Medicine Authors: Kulkarni, H., Zhang, J., Langbein, T., Schuchardt, C., SINGH, A., Mueller, D., Baum, R. Tags: Prostate Therapy I Source Type: research